title: Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.
authors.affiliation: Clinical Assistant Professor at the University of British Columbia in Vancouver, a family physician with a consulting practice in diabetes in the interior of British Columbia, and Medical Lead for the Interior Health Authority Diabetes Strategy. maureen.clement@interiorhealth.ca.
authors.forename: Maureen
authors.initials: M
authors.lastname: Clement
authors.affiliation: Professor, Director of the Division of Endocrinology and Metabolism, and Medical Director of the Clinical Islet Transplant Program at the University of Alberta in Edmonton.
authors.forename: Peter
authors.initials: P
authors.lastname: Senior
mesh_terms: D000328:Adult; D001786:Blood Glucose; D000068896:Canagliflozin / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007657:Ketone Bodies / Q000097:blood; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007657:Ketone Bodies; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin